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Background. The benefits of antiretroviral therapy during early human immunodeficiency virus type 1 (HIV-1)
infection remain unproved.
Methods. A5217 study team randomized patients within 6 months of HIV-1 seroconversion to receive either
36 weeks of antiretrovirals (immediate treatment [IT]) or no treatment (deferred treatment [DT]). Patients were to
start or restart antiretroviral therapy if they met predefined criteria. The primary end point was a composite of
requiring treatment or retreatment and the log10 HIV-1 RNA level at week 72 (both groups) and 36 (DT group).
Results. At the June 2009 Data Safety Monitoring Board (DSMB) review, 130 of 150 targeted participants had
enrolled. Efficacy analysis included 79 individuals randomized $72 weeks previously. For the primary end point, the
IT group at week 72 had a better outcome than the DT group at week 72 (P 5 .005) and the DT group at week 36
(P 5 .002). The differences were primarily due to the higher rate of progression to needing treatment in the DT
group (50%) versus the IT (10%) group. The DSMB recommended stopping the study because further follow-up
was unlikely to change these findings.
Conclusions. Progression to meeting criteria for antiretroviral initiation in the DT group occurred more
frequently than anticipated, limiting the ability to evaluate virologic set point. Antiretrovirals during early HIV-1
infection modestly delayed the need for subsequent treatment.
Clinical Trials Registration. NCT00090779.
The role of antiretroviral therapy (ART) during acute
and early human immunodeficiency virus type 1 (HIV-1)
infection has been an area of investigation for several
years; however, the benefits of such treatment remain
unproved, and best practice for clinical management of
this unique stage of infection remains unknown [1]. The
initiation of ART shortly after HIV-1 infection has been
shown to preserve HIV-1–specific immune responses
that could improve virologic control on discontinuation
of treatment [2–4]. However, prospective observational
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studies have evaluated the effects of early ART followed by
treatment cessation on subsequent virologic control with con-
flicting results [5–15], and few randomized clinical trials have
been performed in the setting of acute and early HIV-1 in-
fection [16–20]. We hypothesized that 36 weeks of ART ad-
ministered to participants within 6 months of acquiring HIV-
1 infection would lower the virologic set point after treatment
discontinuation.
The AIDS Clinical Trials Group (ACTG) Setpoint Study
(A5217) was a multicenter, randomized clinical trial during
which individuals with recent but not acute HIV-1 infection
were randomized to begin immediate treatment (IT) with a 36-
week course of ART and then discontinue treatment, or to defer
treatment (DT) until prespecified criteria for initiation of
therapy were met. During a scheduled interim review, the Data
and Safety Monitoring Board (DSMB) of the National Institute
of Allergy and Infectious Diseases (NIAID) noted a higher than
expected rate of disease progression and subsequent initiation of
ART in the DT group, limiting the ability to compare the
actual virologic set point between the 2 groups. As a result of
these findings in June 2009, the DSMB stated that further
enrollment and follow-up as designed could not be justified and
recommended study discontinuation. We report here on the
data collected through the time of the DSMB recommendations.
METHODS
Study Participants
The study enrolled men and nonpregnant women who were
$18 years of age, were HIV-1 infected within the last 6 months
but beyond the acute phase of infection (with a positive HIV-1
Western blot), and had no prior ART, acceptable laboratory
parameters, and an HIV-1 RNA level $500 copies/mL. Recent
infection was defined as a nonreactive detuned HIV-1 antibody
test consistent with infection of ,6 months duration at the time
of screening, or documented seroconversion (ie, a documented
negative HIV-1 enzyme immunoassay [EIA] or a negative or
indeterminate Western blot within 6 months before the study).
We initially used the Vironostika HIV-1 detuned EIA, with re-
cent infection defined as a standardized optical density mea-
surement #0.75 [21]. In 2008, the Vironostika assay was no
longer available, and the detuned Ora-Quick rapid test was used
to confirm recent infection in the absence of documented se-
roconversion [22–24]. All detuned assays were performed at
either the University of North Carolina at Chapel Hill or the
Blood Systems Research Institute in San Francisco. We excluded
participants who met immunologic or clinical criteria for treat-
ment at entry [25], including the occurrence of Centers for
Disease Control and Prevention (CDC) category B or C diagnoses,
CD41 T-cell count ,350 cells/mm3, or CD41 T-cell percent-
age of ,14%. Baseline genotypic resistance testing was per-
formed on all participants, with therapy adjusted as necessary
when data became available. Individuals with baseline resistance
to .1 component of the initial study regimen were excluded.
The institutional review board at each participating site ap-
proved the study protocol, and written informed consent was
obtained from all participants.
Study Design
ACTG 5217 was a 96-week, multicenter, randomized, open-label
study that began in February 2005 and was performed at 25 sites
in the United States and 2 in Peru. One hundred fifty recently
HIV-1–infected adults were to be randomized 1:1 to the IT
group versus the DT group. Participants in the IT group re-
ceived 36 weeks of ART followed by treatment discontinuation.
Participants in the DT group were followed up off treatment
throughout the study; however, individuals in either group who
met prespecified criteria for treatment initiation or reinitiation
were advised to begin ART.
Screening evaluations included confirmation of recent HIV-1
infection as defined above, genotypic resistance testing, CD41
T-cell count, and HIV-1 RNA level. Baseline and on-study
evaluations occurred at weeks 0, 1, 2, and 4 and every 4 weeks
thereafter for the duration of the study and included CD41 T-cell
count and HIV-1 RNA level, the latter measured using the Roche
Amplicor Monitor assay, version 1.5, at a laboratory certified by
Division of AIDS Virology Quality Assurance program.
Study Treatment
The study provided fixed-dose combination emtricitabine-
tenofovir DF (one 200/300 mg tablet, once daily) and lopi-
navir-ritonavir (200/50 mg tablets, 2 tablets twice daily or 4
tablets once daily) for the first 36 weeks for individuals in the
IT group and for the remaining duration of the study for
individuals in either group who had met eligibility for initi-
ation of ART. However, study participants were allowed to re-
ceive any alternative provider-prescribed potent ART regimen.
Criteria for Initiating ART
Participants in either arm who met protocol-specified criteria
for treatment initiation or reinitiation were advised but not
required to begin treatment. The prespecified criteria for initi-
ating ART were designed to be consistent with treatment
guidelines for chronic infection at the time [25] and included (1)
CD41 T-cell count ,350 cells/mm3 at 2 consecutive determi-
nations $4 weeks apart, $12 weeks into the study or $12 weeks
after treatment discontinuation; (2) confirmed CD41 T-cell
count ,200 cells/mm3 or CD41 T-cell percentage ,14% at any
time during the study; (3) confirmed HIV-1 RNA level
.750 000 copies/mL $4 weeks into the study or .200 000
copies/mL $12 weeks into the study; or (4) CDC category B or C
diagnosis. The time requirements were to accommodate the
fluctuations in CD41 T-cell counts and HIV-1 RNA levels
characteristically seen with recent seroconversion.
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Statistical Analysis
The primary end point was constructed as a composite measure
that consisted of the average viral load at weeks 72 and 76 for
study participants who continued to week 72 off treatment and
an assigned viral load rank for those who met criteria for initi-
ating ART before these study visits and thus could not con-
tribute an off-treatment HIV-1 RNA assessment. Such
individuals were considered to have experienced a poor out-
come and were assigned an HIV-1 RNA rank. The assigned rank
was either the last observed rank carried forward or the worst
rank, according to an analysis plan that was designed to be, if
anything, biased against finding a treatment effect; details of
the algorithm for assigning ranks are provided in the Sup-
plementary appendix. Differences in the primary end point
between the 2 treatment groups at week 72 were then assessed
using the Wilcoxon rank sum 1-sided test, use of which re-
flects the focus of interest in only the 1-sided alternative hy-
pothesis that immediate short-term therapy is superior to delay
in starting therapy. However, at 72 weeks, participants in the IT
group would have been off therapy for 36 weeks, whereas those
in the DT group would have been off therapy for 72 weeks. To
provide additional insight about any benefits of treatment,
a difference in virologic set point observed at 72 weeks would
trigger an additional analysis: comparison of the end point at
week 72 in the IT group (36 weeks after ART was interrupted)
with the end point at week 36 in the DT group (detailed further
in [26]). The secondary end point, time to meeting eligibility for
initiating or reinitiating ART, was assessed via Kaplan-Meier plot
and log-rank test.
Power calculations were based on a 1-sided, 2-sample t test
at a 5 .05, adjusted for the use of methods based on ranked
data. The planned sample size of 75 individuals randomized to
each group provided .90% power to detect a plasma HIV-1
RNA improvement of 0.6 log10 copies/mL in the IT group
compared with the DT group. This provided power of $80% for
the combined 2-step test, using Bonferroni inequality.
Study Monitoring
The initial monitoring plan included 2 interim safety reviews
conducted by the NIAID Therapeutics DSMB. However, given
slower than expected accrual, annual reviews of efficacy and
futility analyses started in the summer of 2008. Subsequently, the
DSMB performed an annual review of safety and efficacy data on




We had enrolled 130 eligible of 150 targeted participants at the
time of the June 2009 DSMB review. Baseline characteristics
were well balanced between the groups (Table 1).
Study Status
At the time of the June 2009 DSMB review, 52 (40%) of 130
participants were still in the study, 52 (40%) had completed the
protocol, 24 (18.5%) had left the study before week 96, and 2 in
the DT group had died. One death was a suicide 14 weeks into
the study, and the other occurred 8 weeks into the study and
was of unknown cause. Reasons for going off study prematurely
are shown in Table 2. Forty-five of 66 (68%) IT participants
had completed 36 weeks of ART, 13 of 66 (20%) were in the
midst of treatment when the study was stopped, 4 (6%) dis-
continued ART prematurely, and 4 (6%) discontinued the
study before week 36. Fifty-five of 66 (83%) treated partic-
ipants chose the study-provided ART regimen, and 88% of all
participants randomized to the IT group achieved complete
virologic suppression by week 24. One participant randomized
to the IT group initiated study medications and was promptly
discontinued and excluded from the efficacy analysis after re-
view of the baseline pol sequence analysis showed multidrug
resistance.
Eligibility for Initiation or Reinitiation of ART
When all 130 participants were included, regardless of length of
time on protocol, 7 of 66 (11%) in the IT group and 23 of 64
(36%) in the DT group met eligibility for initiation/reinitiation
of ART, with 13 (20%) of those in the DT group meeting criteria
within the first 36 weeks. The majority of participants who met
criteria for treatment initiation met immunologic criteria (6 in
IT group, 14 in DT group), and a few met virologic criteria (5 in
DT group). Five individuals met eligibility owing to the occur-
rence of a CDC category B or C event (4 in the DT group, 1 in
the IT group) (Table 3). A total of 5 individuals, all in the DT
group, progressed to AIDSd1 because of persistent herpes sim-
plex infection, 1 because of CD41 T-cell count ,200 cells/mm3,
and 3 because of CD41 T-cell percentage ,14%.
Primary Efficacy Analysis
Efficacy analysis was limited to 79 participants (39 and 40 from
the IT and DT groups, respectively) who had been randomized
$72 weeks before the DSMB review. By week 72, 50% of the 40
DT participants versus 10% of the 39 IT participants had met
criteria for initiation/reinitiation of ART. At week 36, 27.5% of
the 40 DT participants had met criteria for starting ART.
For the primary end point, the IT group at week 72 had
a better outcome than the DT group at 72 weeks (P 5 .005;
1-sided Wilcoxon test) or 36 weeks (P5 .002; 1-sided Wilcoxon
test). The outcome was the same when the analysis was based on
available data for all enrolled participants (ie, including an ad-
ditional 50 participants) instead of being restricted only to 79
who were randomized $72 weeks before the DSMB recom-
mendations. Thus, superiority was demonstrated for the IT
group. Because of the higher-than-expected number of in-
dividuals meeting criteria for initiating ART, the primary
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analysis was highly influenced by the higher rate of progression
in the DT group. Because off-treatment HIV-1 RNA levels were
unobserved for all participants who met criteria for initiating
ART, we were unable to make conclusions regarding the actual
virologic set point.
Time toMeeting Eligibility Criteria for Initiating or Reinitiating ART
A secondary end point was time to meeting eligibility criteria for
initiating or reinitiating ART, which was significantly shorter in
the DT group than in the IT group using data up to 76 and
96 weeks (P , .001 for both, by log-rank test). Figure 1 shows
the time to meeting eligibility criteria for starting ART over the
96 weeks of the study. In a different analysis that compared the
first 36 weeks of the study for participants in the DT group and
the period from weeks 36 to 72 for participants in the IT group,
the time to meeting criteria for initiating ART remained
shorter in the DT group than in the IT group (Figure 2). Using
the time when ART was interrupted (week 36) as the time
origin for the IT group and week 0 as the time origin for the DT
group, the curves remain significantly different (P 5 .035; log-
rank test), but the analysis includes only those in the IT group who
continued ART through week 36 (n 5 49), compared with all in
the DT group (n 5 64), and therefore it is not a randomized
comparison. Treated participants experienced an additional delay
(16 weeks) beyond the 36 weeks of treatment before failures
began to occur.
Proportional hazard models adjusted for treatment group
were used to evaluate whether any of the baseline characteristics
predicted time to meeting criteria for initiating ART. Baseline
CD41 T-cell count ,540 cells/mm3 and baseline viral load $4.4
Table 1. Baseline Characteristics
Characteristic














Male 58 (88) 59 (92) 117 (90) 34 (87) 40 (100) 74 (94)
Female 8 (12) 5 (8) 13 (10) 5 (13) 0 (0) 5 (6)
Age, median (IQR), y 34 (25–40) 33 (27–42) 33 (26–42) 37 (23–42) 36.0 (28.5–42.5) 36 (26–42)
Race
White 49 (74) 56 (88) 105 (81) 31 (79) 38 (95) 69 (87)
Black/African American 10 (15) 3 (5) 13 (10) 6 (15) 2 (5) 8 (10)
Other/unknown 7 (11) 5 (8) 12 (9) 2 (5) 0 (0) 2 (3)
Ethnicity
Hispanic or Latino 14 (21) 9 (14) 23 (18) 7 (18) 1 (3) 8 (10)
Not Hispanic or Latino 52 (79) 55 (86) 107 (82) 32 (82) 39 (98) 71 (90)
Transmission risk
MSM 52 (79) 55 (86) 107 (82) 31 (79) 36 (90) 67 (85)
Heterosexual 10 (15) 7 (11) 17 (13) 8 (21) 3 (8) 11 (14)
IVDU 1 (2) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
MSM and IVDU 3 (5) 1 (2) 4 (3) 0 (0) 1 (3) 1 (1)
Unknown 0 (0) 1 (2) 1 (1) 0 (0) 0 (0) 0 (0)
CD41 T-cell count,
median (IQR), cells/mm3a
514 (415–671) 557 (441–721) 540 (435–697) 488 (402, 671) 552 (435–704) 534 (415–697)
CD41 T-cell count,
cells/mm3
201–350 4 (6) 2 (3) 6 (5) 3 (8) 2 (5) 5 (6)
351–500 26 (39) 24 (38) 50 (38) 17 (44) 14 (35) 31 (39)
.500 36 (55) 38 (59) 74 (57) 19 (49) 24 (60) 43 (54)
HIV-1 RNA, median (IQR),
log10 copies/mL
a
4.4 (3.9–4.8) 4.4 (4.0–4.7) 4.4 (4.0–4.7) 4.4 (3.9–4.8) 4.4 (4.1–4.9) 4.4 (4.0–4.9)
HIV-1 RNA, copies/mL
,10 000 17 (26) 16 (25) 33 (25) 10 (26) 8 (20) 18 (23)
$10 000 49 (74) 48 (75) 97 (75) 29 (74) 32 (80) 61 (77)
Except where otherwise indicated, data represent No. (%) of subjects. P . .05 for all comparisons between treatment groups.
Abbreviations: DT, deferred treatment; HIV-1, human immunodeficiency virus, type 1; IQR, interquartile range; IT, immediate treatment; IVDU, intravenous drug use;
MSM, men who have sex with men.
a Baseline CD41 T-cell counts and baseline HIV-1 RNA levels were the values at study entry.
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log10 copies/mL were associated with shorter time to meeting
criteria for starting ART (hazard ratio, 4.49 [P5 .0003] and 3.99
[P 5 .0007], respectively). No significant interaction effect was
found between treatment group and baseline CD41 T-cell count
or baseline HIV-1 RNA value.
Observed HIV-1 RNA Values
Among participants who contributed an observed week 72 and/
or week 76 HIV-1 RNA value (26 of 39 [67%] in the IT group
and 11 of 40 [27.5%] in the DT group), the mean HIV-1 RNA
levels at weeks 72 and 76 were similar between the 2 treat-
ment groups (3.99 log10 copies/mL in the IT group and 4.15
log10 copies/mL in the DT group). Among participants (26 in the
IT group and 22 in the DT group) who contributed an observed
week 72 and/or week 76 HIV-1 RNA value (IT group) or an
observed week 36 and/or week 40 HIV-1 RNA value (DT group),
the point estimate for the mean HIV-1 RNA level at week 36 in
the DT group was higher than that measured at week 72 in the
IT group (4.37 log10 copies/mL vs 3.99 log10 copies/mL), but
this finding must be interpreted with caution, given that the
confidence intervals overlap and the remaining individuals
were a selected subgroup of the original participants. The
mean log10 copies/mL change in HIV-1 RNA from baseline
was 20.29 at 72 weeks in the IT group and 0.07 at 36 weeks in
the DT group (Table 4).
DISCUSSION
This is the largest randomized controlled trial designed to assess
whether ART initiated during early but not acute HIV-1
Table 3. Summary of Eligibility Criteria Met for Initiation of Antiretroviral Therapy (ART)
Criteria
Treatment Group, No.
Immediate (n 5 66) Deferred (n 5 64)
Total meeting ART criteria 7 (11%) 23 (36%)
CD41 T-cell percentage ,14% and HIV-1 RNA .200 000 copies/mLa 0 1
CD41 T-cell count ,350 cells/mm3 (2 consecutive visits) 6 10
CD41 T-cell percentage ,14% 0 2
CD41 T-cell count ,200 cells/mm3 0 1
HIV-1 RNA .750 000 copies/mL (2 consecutive visits) 0 1
HIV-1 RNA .200 000 copies/mL (2 consecutive visits) 0 4
CDC category B or C disease 1 4
Herpes simplex for .1 month 0 1
Oral hairy leukoplakia 0 1
Fatigue 1 0
Idiopathic thrombocytopenic purpura 0 2
Abbreviations: CDC, Centers for Disease Control and Prevention; HIV-1, human immunodeficiency virus, type 1.
a Only the first criterion that study participants met was counted in the summary of eligibility for ART initiation. One individual met 2 eligibility criteria
simultaneously. Laboratory values meeting eligibility criteria were confirmed over 2 consecutive visits.
Table 2. Summary of Study Status at the Time of Data and Safety Monitoring Board Recommendations
Status
Treatment Group, No. (%)
Immediate (n 5 66) Deferred (n 5 64) Total (n 5 130)
In study 29 (44) 23 (36) 52 (40)
Died 0 (0) 2 (3) 2 (2)
Completed protocol 26 (39) 26 (41) 52 (40)
Premature discontinuationa 11 (17) 13 (20) 24 (18)
Subject refused further participation 4 (36) 2 (15) 6 (25)
Nonadherence to study requirements 0 (0) 1 (8) 1 (4)
Subject relocated, no remote follow-up planned 2 (18) 8 (62) 10 (42)
Subject could not be contacted 3 (27) 2 (15) 5 (21)
Investigator/clinician decision 1 (9) 0 (0) 1 (4)
Other (pregnancy) 1 (9) 0 (0) 1 (4)
a Four subjects (all in the deferred treatment group) met criteria for initiation of antiretroviral therapy before prematurely leaving the study.
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infection is associated with better virologic outcomes than de-
ferred ART. The study demonstrated a better outcome in the IT
group, as measured by the composite end point at week 72 as
well as at week 36 for the DT group versus week 72 for the IT
group. Owing to the higher-than-anticipated rates of pro-
gression and, consequently, initiation of therapy, the difference
in virologic set points between the 2 groups could not be sta-
tistically evaluated. In addition, participants in the IT group
took significantly longer to meet the criteria for starting ART.
Treated participants appear to have been protected not only
while on treatment but also for a brief period of time thereafter.
Thus, a limited period of ART during early HIV-1 infection
delayed the need for subsequent initiation of long-term ART.
The best practice for the clinical management of primary
HIV-1 infection remains unknown. Although prospective ob-
servational data from the HIV-CAUSAL Collaboration dem-
onstrated the lowest mortality rate (6/1000 person-years) in
seroconverters who started ART, compared with the overall
mortality rate of 10/1000 person-years among individuals with
established infection who started ART [27], no randomized
clinical trials to date provide definitive recommendations for
ART use in this patient population [16–20]. Efforts to evaluate
the potential effect of ART on virologic set point in recently
infected individuals have been limited, in part because of the
challenges involved in identifying recently infected persons [5–15].
A study comparing 58 individuals who received ART during
primary HIV-1 infection with 116 who remained untreated
found no differences in virologic set point 12 months after
withdrawal of effective ART [6]. Among the very few ran-
domized clinical trials evaluating the impact of ART on viro-
logic set point in recently infected persons, no persistent
significant differences have been observed in HIV-1 RNA levels
[16, 17, 20]. Like our study, a recently completed randomized
controlled trial of temporary treatment versus no treatment
during acute HIV-1 infection in the Netherlands observed
a delay in the need for long-term ART in the immediate
treatment group, although the delay appeared to be longer in
the Dutch study [20]. However, whether such a delay in
treatment yields durable or substantial clinical benefits remains
unknown. A substudy of A5217 is underway to address whether
immediate versus deferred treatment during primary infection
results in improvements in markers of inflammation and im-
mune activation, which may provide further insight into the
potential benefits of treating primary infection.
Perhaps the most compelling finding of the A5217 study is
that the time between the diagnosis of early infection and the
need for initiation of ART was shorter than anticipated in the
DT group. Investigators from the CASCADE study evaluated
14 387 individuals with well-estimated dates of HIV serocon-
version to predict the proportion of participants with CD41
Figure 1. Time to meeting eligibility criteria for initiation or reinitiation of antiretroviral therapy (ART) for the immediate treatment (IT) and deferred
treatment (DT) groups over the 96 weeks of the study; times were significantly longer in the IT group (P , .001; log–rank test).
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counts below certain thresholds at various years after serocon-
version [28]. Their model, which incorporated data from
a median 4.4 years of follow-up since seroconversion while AIDS
free and ART naive, predicted that 27% of individuals would
develop a CD41 count ,350 cells/mm3 within 2 years after
seroconversion. Our observation that half of the participants in
the DT group who were included in the primary analysis met
criteria for treatment initiation by week 72 would be consistent
with a more rapid progression to this threshold. The slower rate
of disease progression observed in the CASCADE cohort study
may be related to a treatment selection bias resulting from ex-
clusion of those persons from the analysis who received early
treatment because of a greater perceived risk for disease pro-
gression. In addition, some observational cohort studies have
found evidence of an increase in HIV virulence over time, as
evidenced by higher postseroconversion HIV-1 RNA levels,
lower postseroconversion CD41 T cells, and/or higher viral
replicative capacity [29–33], although these observations are not
supported by findings of other studies [34, 35]. Although the
median baseline CD41 T-cell count in the current study is not
Table 4. Observed log10 HIV-1 RNA Values
HIV-1 RNA Values Immediate Therapy Deferred Therapy
HIV-1 RNA, mean (SE), log10 copies/mL
Week 0 4.36 (0.10) (n 5 39) 4.50 (0.09) (n 5 40)
Week 36 . 4.37 (0.09) (n 5 22)
Week 72 3.99 (0.13) (n 5 26) 4.15 (0.13) (n 5 11)
Change in HIV-1 RNA from weeks 0 to 36, mean (SE), log10 copies/mL NA 0.07 (0.09)
Change in HIV-1 RNA from weeks 0 to 72, mean (SE), log10 copies/mL 20.29 (0.16) 0.01 (0.17)
Abbreviations: HIV-1, human immunodeficiency virus, type 1; NA, not applicable; SE, standard error.
Figure 2. Time to meeting eligibility criteria for initiation or reinitiation of antiretroviral therapy (ART) for the immediate treatment (IT) and deferred
treatment (DT) groups. The time origin for the IT group was the time when ARTwas interrupted (week 36), and the time origin for the DT group was week 0.
The curves remain significantly different (P5 .035 by log–rank test), but the analysis includes only those in the IT group who continued ART through week 36
(n 5 49), compared with all in the DT group (n 5 64), and therefore it is not a truly randomized comparison.
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inconsistent with this hypothesis, the relatively small number of
participants is insufficient to support or refute the possibility of
changing virulence in the epidemic.
Recently revised treatment guidelines recommend treatment
initiation at higher CD41 T-cell count thresholds [36, 37]. These
guidelines consider emerging data highlighting the con-
sequences of untreated HIV-1 infection and the potential role
of ART in preventing serious non-AIDS conditions, which may
result from the persistent immune activation and systemic
inflammation associated with uncontrolled viral replication
[27, 38–41]. The results of our current study may be of in-
terest to clinicians and patients struggling with the decision of
whether to initiate ART during recent HIV infection. Our
results suggest that if immediate therapy is not begun, pro-
gression to meeting standard criteria for ART initiation may
occur more rapidly than expected, especially with changing
treatment paradigms.
Limitations of the study include the methods currently avail-
able for classifying study participants as having recent HIV in-
fection. Detuned assays, used to confirm early infection for 78%
of the participants, are limited in precision [42, 43]. The po-
tential errors in disease stage classification were thought to favor
exclusion of those with recent infection rather than inappropriate
inclusion of participants with advanced HIV. We are unable to
exclude, however, the possibility of this latter type of mis-
classification contributing to the more rapid rate of progression.
Another possible contribution to a selection bias favoring rapid
progression for this cohort may result from oversampling of
individuals with symptomatic seroconversion syndromes (55%
overall), who are more likely to seek medical attention and may
experience more rapid disease progression [44, 45]. Finally, it is
not possible to extrapolate the observed study results to in-
dividuals who present with acute HIV infection (HIV-1 RNA
positive, HIV-1 antibody negative), because our study enrolled
only participants with recent but not acute infection.
In conclusion, this randomized, controlled trial of immediate
versus deferred ART in the setting of recent HIV-1 infection
demonstrated a treatment effect in favor of immediate treat-
ment. A limited period of ART during early HIV-1 infection
modestly delayed the need for subsequent initiation of long-
term ART. The study was unable to answer the initial question
regarding virologic set point, and durable clinical benefits of this
strategy remain unproved. However, the higher than anticipated
rate of disease progression among untreated individuals, which
prevented us from drawing conclusions regarding the virologic
set point, is a compelling finding of this study and contributes to
the growing body of evidence favoring earlier treatment.
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